Children’s Hospital of Philadelphia (CHOP) is at the forefront of research and development of new therapies to treat pediatric leukemias, brain tumors, neuroblastoma and other cancers. The Cancer Center’s research focus is not only on cancer treatments, but also on prevention and treatment of the physical and psychological complications of those therapies.
CHOP doctors and researchers helped develop the first national and international clinical trials for an immunotherapy known as chimeric antigen receptor (“CAR”) T-cell therapy for children with advanced acute lymphoblastic leukemia (ALL).
CHOP is the host site for the Children’s Brain Tumor Tissue Consortium, an organization of children’s hospitals from around the world that are advancing research by sharing a large bank of pediatric brain tumor tissue.
The Cancer Center at CHOP leads the 20 Children’s Oncology Group (COG) Phase I institutions, enabling the fast-tracking of novel therapies that require testing in children. COG is an international coalition of more than 230 children’s cancer hospitals. Many Cancer Center physicians lead COG strategy groups, biology studies and clinical trials in leukemia, neuroblastoma, brain tumors, sarcomas, developmental therapeutics, cancer survivorship and supportive care.